

February 15, 2024

# **Q3FY24 Result Update**

☑ Change in Estimates | ☑ Target | ■ Reco

# **Change in Estimates**

	Cu	rrent	Prev	/ious
	FY25E	FY26E	FY25E	FY26E
Rating	RE	DUCE	REI	DUCE
Target Price	1,	,985	1,	881
Sales (Rs. m)	82,181	91,307	78,693	87,295
% Chng.	4.4	4.6		
EBITDA (Rs. m)	14,546	16,186	14,346	16,106
% Chng.	1.4	0.5		
EPS (Rs.)	68.3	76.3	67.2	75.2
% Chng.	1.5	1.5		

# **Key Financials - Consolidated**

Y/e Mar	FY23	FY24E	FY25E	FY26E
Sales (Rs. m)	79,721	76,406	82,181	91,307
EBITDA (Rs. m)	12,894	12,175	14,546	16,186
Margin (%)	16.2	15.9	17.7	17.7
PAT (Rs. m)	8,520	8,261	9,309	10,414
EPS (Rs.)	62.5	60.6	68.3	76.3
Gr. (%)	(20.1)	(3.0)	12.7	11.9
DPS (Rs.)	7.5	7.3	8.2	9.2
Yield (%)	0.3	0.3	0.4	0.4
RoE (%)	22.9	18.6	17.8	17.1
RoCE (%)	28.9	22.2	21.3	20.7
EV/Sales (x)	3.9	4.1	3.8	3.4
EV/EBITDA (x)	24.2	25.5	21.6	19.4
PE (x)	36.5	37.7	33.4	29.9
P/BV (x)	7.6	6.5	5.5	4.8

Key Data	DPNT.BO   DN IN
52-W High / Low	Rs.2,521 / Rs.1,749
Sensex / Nifty	72,050 / 21,911
Market Cap	Rs.311bn/ \$ 3,749m
Shares Outstanding	136m
3M Avg. Daily Value	Rs.956.91m

# **Shareholding Pattern (%)**

Promoter's	49.13
Foreign	6.48
Domestic Institution	18.87
Public & Others	25.52
Promoter Pledge (Rs bn)	-

### **Stock Performance (%)**

	1M	6M	12M
Absolute	(6.0)	11.1	27.0
Relative	(4.3)	0.9	8.0

### Swarnendu Bhushan

swarnendubhushan@plindia.com | 91-22-66322260

# Saurabh Ahire

saurabhahire@plindia.com |

# **Deepak Nitrite (DN IN)**

Rating: REDUCE | CMP: Rs2,283 | TP: Rs1,985

# Phenol utilization remains high

## **Quick Pointers:**

- MoU worth Rs90bn with the Government of Gujarat on January 31, 2024; adding to the previous MoU worth Rs50bn as of May 23, 2023 for an aggregate of ~Rs140bn
- Phenolics plant utilization at 140-150% for Q3FY24

Deepak Nitrite (DN) topline grew 13% QoQ anchored by solid growth in the Phenolics segment, driven by robust volume growth and improved realization. Advanced Intermediates segment experienced subdued demand recovery in agrochemicals, textiles and dyes & pigments segment. The company has announced plans for large scale capex including brownfield and greenfield expansion and expects to commence all the projects before 2027. The stock is currently trading at 30x FY26E EPS and 19x FY26E EV/EBITDA. We anticipate ~7% EPS CAGR over FY23-26E. We value the stock at 26x P/E at FY26 EPS and retain 'Reduce' rating with TP of Rs1,985(earlier Rs1,935).

- Segmental Performance: Advanced intermediates revenue -17.5%/0.6% YoY & QoQ to Rs6.7bn, while EBIT margins stood at 14% for the quarter. Phenolics division showed impressive volume growth with revenue up by 14.2%/20.5% YoY & QoQ to Rs13.4bn. Phenolics plant operated at a utilization of approximately 140%.
- Consolidated revenue stood at Rs 20bn (1% YoY/ 13% QoQ; PLe: 17.3bn), driven by 14% YoY/20% QoQ increase in Phenolics division revenue to Rs13.5bn. For 9MFY24, topline declined by 7.6% to Rs55.5bn from Rs60bn, while EBITDA & PAT margins remained flat at 32.3%/10% respectively.
- Gross profit margin was at 31.7% (vs 34.4% in Q2FY24 and 32.8% in Q3FY23; PLe: 32.9), inline with the actual margin.
- Even though topline improved 13% QoQ, EBITDA came in flat at Rs3bn (vs Rs3.1bn in Q3FY23 and Rs3bn in Q2FY24), due to significant increase in raw material cost. EBITDA margin came at 15.2% (vs 15.8% in Q3FY23 and 17% in Q2FY24). 9MFY24 EBITDA stood at Rs8.1bn, 13% down YoY.
- Reported PAT came in flat at Rs2bn (-3.4% YoY/ 1.5% QoQ), while margins were at 10% in Q3FY24 vs 10.5% & 11.5% in Q3FY23 & Q2FY24 respectively.
- Concall takeaways: Global chemical industry continues to witness adverse conditions (2) Chinese suppliers taking steps to destock the inventory of intermediates (3) Segmental Performance: Phenolic segment showed robust growth, driven by volume gains and improved realizations, subdued demand recovery in industries such as agrochemicals, textiles and dyes, and pigment, healthy demand for construction infrastructure and home care (4) Ongoing projects such as photohalogenation, high pressure fluorination, acid unit and others are progressing well and are expected to be commissioned as planned (5) High pressure fluorination, acid unit commissioning is anticipated in this



quarter (5) Expansion projects such as MIBK, MIBC and hydrogenation going as per plan (6) Additional MoU worth Rs90bn signed with Gujrat government, which leads to total MoU of Rs140bn for manufacturing of polycarbonate resins, methyl methacrylate MMA, polymethyl methacrylate, PMMA resins, all projects to be completed by 2027, Rs20bn worth investment to be commissioned in coming quarter (7) Domestic: Export revenue mix came in at 15.72: 4.51bn (8) The company is net debt free (9) DNL has invested Rs170mn in Deepak, Oman Industries to acquire 32% stake (10) For Agrochemicals Q4FY24 is expected to be better than Q3FY24 (11) All new projects which are expected to be commissioned in CY24 are expected to reach optimal level in FY26 (12) Phenol plant, which is operating at 140%-150% capacity, operated at 88000 tons for Q3FY24, total yearly capacity is around 350,000 tons (13) Phenol total volume growth is around 17% to 20% in cumulative in 9MFY24 (14) New investments to add 2% to 3% over current EBITDA margins (15) Fragile recovery is expected for Advanced intermediate segment.

Exhibit 1: Q3FY24 Result Overview - Consolidated (Rs mn)

Y/e March	Q3FY24	Q3FY23	YoY gr. (%)	Q3FY24E	% Var.	Q2FY24	QoQ gr. (%)	9MFY24	9MFY23	YoY gr. (%)
Net Sales	20,092	19,911	0.9	17,384	15.6	17,781	13.0	55,556	60,107	(7.6)
Gross Profit	6,366	6,525	(2.4)	5,714	11.4	6,122	4.0	17,935	19,413	(7.6)
Margin (%)	31.7	32.8		32.9	(3.6)	34.4		32.3	32.3	
EBITDA	3,047	3,146	(3.2)	2,846	7.0	3,023	0.8	8,167	9,414	(13.3)
Margin (%)	15.2	15.8		16.4	(7.4)	17.0		14.7	15.7	
Other Income	136	134	1.4	166	(18.4)	170	(20.5)	625	350	78.4
Depreciation	417	411	1.4	445	(6.4)	394	5.7	1192	1254	(4.9)
EBIT	2,765	2,869	(3.6)	2,567	7.7	2,799	(1.2)	7,599	8,511	(10.7)
Interest	29	58	(49.7)	40	(26.3)	27	9.3	74	203	(63.5)
PBT before exp	2,736	2,810	(2.6)	2,527	8.3	2,772	(1.3)	7,525	8,307	(9.4)
Total Tax	715	720	(0.6)	704	1.6	721	(0.8)	1,955	2,126	(8.0)
ETR (%)	26.1	25.6		27.9	(6.1)	26.0		26.0	25.6	
Adj. PAT	2,020	2,091	(3.4)	1,823	10.8	2,051	(1.5)	5,570	6,181	(9.9)
Exceptional Items	0	0	-	0	-	0		0	0	-
PAT	2,020	2,091	(3.4)	1,823	10.8	2,051	(1.5)	5,570	6,181	(9.9)

Source: Company, PL




Exhibit 2: Q3FY24 - Segmental Performance (Rs mn)

Y/E March	Q3FY24	Q3FY23	YoY gr.	Q2FY24	QoQ gr.	9MFY24	9MFY23	YoY gr.
Advaned Intermediates	6,743	8,178	-17.5%	6,702	0.6%	20,528	22,331	-8.1%
Phenolics	13,493	11,816	14.2%	11,201	20.5%	35,373	38,006	-6.9%
Intersegment	144	83	73.3%	123	17.3%	345	230	50.4%
Total Revenue	20,092	19,911	0.9%	17,781	13.0%	55,556	60,107	-7.6%
Advaned Intermediates	937	1,475	-36.5%	1,034	-9.4%	3,120	4,185	-25.5%
Phenolics	1,798	1,270	41.5%	1,704	5.5%	4,378	4,174	4.9%
Interest	29	58	-49.7%	27	9.3%	74	203	-63.5%
Other unallocable expenses	(31)	(124)	-75.1%	(61)	-49.6%	(102)	(151)	-32.5%
Total EBIT	2,736	2,810	-2.6%	2,772	-1.3%	7,525	8,307	-9.4%
EBIT Margins								
Advaned Intermediates	13.9%	18.0%		15.4%		15.2%	18.7%	
Phenolics	13.3%	10.7%		15.2%		12.4%	11.0%	


Source: Company, PL

Exhibit 3: Rev to grow at 6% CAGR (FY23-26E)




Source: Company, PL

Exhibit 4: Stable margin on spread normalization




Source: Company, PL

Exhibit 5: PAT margins at 12%




Source: Company, PL

Exhibit 6: Return Ratios to hover around 18-20%




Source: Company, PL

**Exhibit 7: Strong FCF despite capex** 



Source: Company, PL

Exhibit 8: Net Debt/Equity at 0.1x



Source: Company, PL

February 15, 2024



# **Financials**

Income Statement	(Rs m)
------------------	--------

income Statement (NS III)				
Y/e Mar	FY23	FY24E	FY25E	FY26E
Net Revenues	79,721	76,406	82,181	91,307
YoY gr. (%)	17.2	(4.2)	7.6	11.1
Cost of Goods Sold	53,475	51,179	53,923	60,384
Gross Profit	26,246	25,227	28,258	30,922
Margin (%)	32.9	33.0	34.4	33.9
Employee Cost	3,183	3,501	3,851	4,236
Other Expenses	10,169	9,551	9,862	10,500
EBITDA	12,894	12,175	14,546	16,186
YoY gr. (%)	(19.6)	(5.6)	19.5	11.3
Margin (%)	16.2	15.9	17.7	17.7
Depreciation and Amortization	1,663	1,781	2,323	2,540
EBIT	11,231	10,394	12,222	13,646
Margin (%)	14.1	13.6	14.9	14.9
Net Interest	248	114	250	250
Other Income	476	764	468	520
Profit Before Tax	11,459	11,044	12,441	13,917
Margin (%)	14.4	14.5	15.1	15.2
Total Tax	2,939	2,783	3,131	3,503
Effective tax rate (%)	25.6	25.2	25.2	25.2
Profit after tax	8,520	8,261	9,309	10,414
Minority interest	-	-	-	-
Share Profit from Associate	-	-	-	-
Adjusted PAT	8,520	8,261	9,309	10,414
YoY gr. (%)	(20.1)	(3.0)	12.7	11.9
Margin (%)	10.7	10.8	11.3	11.4
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	8,520	8,261	9,309	10,414
YoY gr. (%)	(20.1)	(3.0)	12.7	11.9
Margin (%)	10.7	10.8	11.3	11.4
Other Comprehensive Income	-	_	-	-
Total Comprehensive Income	8,520	8,261	9,309	10,414
Equity Shares O/s (m)	136	136	136	136
EPS (Rs)	62.5	60.6	68.3	76.3

Source: Company Data, PL Research

<b>Balance Sheet Abstract (Rs</b>	m)			
Y/e Mar	FY23	FY24E	FY25E	FY26E
Non-Current Assets				
Gross Block	26,705	35,705	48,205	60,705
Tangibles	26,705	35,705	48,205	60,705
Intangibles	-	-	-	-
Acc: Dep / Amortization	7,106	8,888	11,211	13,751
Tangibles	7,106	8,888	11,211	13,751
Intangibles	-	-	-	-
Net fixed assets	19,599	26,817	36,994	46,954
Tangibles	19,599	26,817	36,994	46,954
Intangibles	-	-	-	-
Capital Work In Progress	2,826	2,826	2,826	2,826
Goodwill	-	-	-	-
Non-Current Investments	3,794	3,794	3,794	3,794
Net Deferred tax assets	(1,566)	(1,566)	(1,566)	(1,566)
Other Non-Current Assets	-	-	-	-
Current Assets				
Investments	-	-	-	-
Inventories	8,931	8,584	9,039	10,039
Trade receivables	13,095	12,551	13,499	12,508
Cash & Bank Balance	400	4,580	3,457	1,281
Other Current Assets	2,644	2,534	2,726	3,028
Total Assets	51,287	61,685	72,334	80,429
Equity				
Equity Share Capital	273	273	273	273
Other Equity	40,627	47,896	56,088	65,251
Total Networth	40,900	48,169	56,361	65,524
Non-Current Liabilities				
Long Term borrowings	545	4,000	6,000	4,000
Provisions	-	-	-	-
Other non current liabilities	-	-	-	-
Current Liabilities				
ST Debt / Current of LT Debt	-	-	-	-
Trade payables	6,618	6,361	6,698	7,439
Other current liabilities	1,659	1,590	1,710	1,900
Total Equity & Liabilities	51,287	61,685	72,334	80,429

Source: Company Data, PL Research

February 15, 2024 5



Cash Flow (Rs m)				
Y/e Mar	FY23	FY24E	FY25E	FY26E
PBT	11,459	11,044	12,441	13,917
Add. Depreciation	1,663	1,781	2,323	2,540
Add. Interest	309	114	250	250
Less Financial Other Income	476	764	468	520
Add. Other	(246)	-	-	-
Op. profit before WC changes	13,185	12,939	15,014	16,707
Net Changes-WC	(4,085)	675	(1,138)	620
Direct tax	(2,600)	(2,783)	(3,131)	(3,503)
Net cash from Op. activities	6,499	10,831	10,745	13,824
Capital expenditures	(3,599)	(9,000)	(12,500)	(12,500)
Interest / Dividend Income	22	-	-	-
Others	816	-	-	-
Net Cash from Invt. activities	(2,761)	(9,000)	(12,500)	(12,500)
Issue of share cap. / premium	-	-	-	-
Debt changes	(2,523)	3,455	2,000	(2,000)
Dividend paid	(955)	(992)	(1,118)	(1,250)
Interest paid	(233)	(114)	(250)	(250)
Others	120	-	-	-
Net cash from Fin. activities	(3,591)	2,350	632	(3,500)
Net change in cash	148	4,181	(1,123)	(2,177)
Free Cash Flow	2,900	1,831	(1,755)	1,324

Source: Company Data, PL Research

Quarterly Financials (Rs m)

Y/e Mar	Q4FY23	Q1FY24	Q2FY24	Q3FY24
Net Revenue	19,614	17,683	17,781	20,092
YoY gr. (%)	4.8	(14.1)	(9.4)	0.9
Raw Material Expenses	12,781	12,236	11,658	13,726
Gross Profit	6,832	5,447	6,122	6,366
Margin (%)	34.8	30.8	34.4	31.7
EBITDA	3,480	2,098	3,023	3,047
YoY gr. (%)	(15.2)	(41.1)	11.6	(3.2)
Margin (%)	17.7	11.9	17.0	15.2
Depreciation / Depletion	409	381	394	417
EBIT	3,070	1,717	2,628	2,630
Margin (%)	15.7	9.7	14.8	13.1
Net Interest	45	18	27	29
Other Income	126	319	170	136
Profit before Tax	3,152	2,017	2,772	2,736
Margin (%)	16.1	11.4	15.6	13.6
Total Tax	813	518	721	715
Effective tax rate (%)	25.8	25.7	26.0	26.1
Profit after Tax	2,339	1,499	2,051	2,020
Minority interest	-	-	-	-
Share Profit from Associates	-	-	-	-
Adjusted PAT	2,339	1,499	2,051	2,020
YoY gr. (%)	(11.8)	(36.1)	17.7	(3.3)
Margin (%)	11.9	8.5	11.5	10.1
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	2,339	1,499	2,051	2,020
YoY gr. (%)	(11.8)	(36.1)	17.7	(3.3)
Margin (%)	11.9	8.5	11.5	10.1
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	2,339	1,499	2,051	2,020
Avg. Shares O/s (m)	136	136	136	136
EPS (Rs)	17.2	11.0	15.1	14.9

Source: Company Data, PL Research

Key Financial Metrics							
Y/e Mar	FY23	FY24E	FY25E	FY26E			
Per Share(Rs)							
EPS	62.5	60.6	68.3	76.3			
CEPS	74.7	73.6	85.3	95.0			
BVPS	299.9	353.1	413.2	480.4			
FCF	21.3	13.4	(12.9)	9.7			
DPS	7.5	7.3	8.2	9.2			
Return Ratio(%)							
RoCE	28.9	22.2	21.3	20.7			
ROIC	21.7	17.5	17.2	16.1			
RoE	22.9	18.6	17.8	17.1			
Balance Sheet							
Net Debt : Equity (x)	-	0.0	0.0	0.0			
Net Working Capital (Days)	71	71	70	60			
Valuation(x)							
PER	36.5	37.7	33.4	29.9			
P/B	7.6	6.5	5.5	4.8			
P/CEPS	30.6	31.0	26.8	24.0			
EV/EBITDA	24.2	25.5	21.6	19.4			
EV/Sales	3.9	4.1	3.8	3.4			
Dividend Yield (%)	0.3	0.3	0.4	0.4			

Source: Company Data, PL Research





Recommendation History								
No.	Date	Rating	TP (Rs.) Share Pr	TP (Rs.) Share Price (Rs.)				
1	08-Jan-24	Reduce	1,881	2,451				
2	10-Nov-23	Reduce	1,935	2,076				
3	17-Oct-23	Reduce	1,854	2,125				
4	09-Oct-23	Reduce	1,803	2,108				
5	09-Aug-23	Reduce	1,803	2,092				

# **Analyst Coverage Universe**

Sr. No.	Company Name	Rating	TP (Rs)	Share Price (Rs)
1	Aarti Industries	Reduce	599	663
2	Bharat Petroleum Corporation	Sell	381	504
3	Bharti Airtel	Accumulate	1,225	1,134
4	Clean Science and Technology	Hold	1,425	1,461
5	Deepak Nitrite	Reduce	1,881	2,451
6	Fine Organic Industries	Hold	4,575	4,496
7	GAIL (India)	Reduce	157	172
8	Gujarat Fluorochemicals	Hold	3,727	3,616
9	Gujarat Gas	Hold	548	562
10	Gujarat State Petronet	Accumulate	402	353
11	Hindustan Petroleum Corporation	Sell	284	432
12	Indian Oil Corporation	Sell	100	143
13	Indraprastha Gas	Hold	382	405
14	Jubilant Ingrevia	Hold	433	439
15	Laxmi Organic Industries	Sell	221	271
16	Mahanagar Gas	Reduce	1,124	1,345
17	Mangalore Refinery & Petrochemicals	Sell	106	134
18	Navin Fluorine International	Accumulate	3,727	3,262
19	NOCIL	Reduce	254	270
20	Oil & Natural Gas Corporation	Hold	262	258
21	Oil India	Accumulate	538	499
22	Petronet LNG	Sell	212	268
23	Reliance Industries	Accumulate	2,912	2,735
24	SRF	Reduce	2,127	2,320
25	Vinati Organics	Reduce	1,626	1,613

# PL's Recommendation Nomenclature (Absolute Performance)

 Buy
 : > 15%

 Accumulate
 : 5% to 15%

 Hold
 : +5% to -5%

 Reduce
 : -5% to -15%

 Sell
 : < -15%</td>

Not Rated (NR) : No specific call on the stock
Under Review (UR) : Rating likely to change shortly



# **ANALYST CERTIFICATION**

# (Indian Clients)

We/l, Mr. Swarnendu Bhushan- IIT, MBA Finance, Mr. Saurabh Ahire- MBA, Passed CFA Level II Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

### (US Clients)

The research analysts, with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is or will be directly related to the specific recommendation or views expressed in this research report.

# **DISCLAIMER**

### **Indian Clients**

Prabhudas Lilladher Pvt. Ltd, Mumbai, India (hereinafter referred to as "PL") is engaged in the business of Stock Broking, Portfolio Manager, Depository Participant and distribution for third party financial products. PL is a subsidiary of Prabhudas Lilladher Advisory Services Pvt Ltd. which has its various subsidiaries engaged in business of commodity broking, investment banking, financial services (margin funding) and distribution of third party financial/other products, details in respect of which are available at www.plindia.com.

This document has been prepared by the Research Division of PL and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security.

The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein.

Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient's particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor.

Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication.

PL may from time to time solicit or perform investment banking or other services for any company mentioned in this document.

PL is a registered with SEBI under the SEBI (Research Analysts) Regulation, 2014 and having registration number INH000000271.

PL submits that no material disciplinary action has been taken on us by any Regulatory Authority impacting Equity Research Analysis activities.

PL or its research analysts or its associates or his relatives do not have any financial interest in the subject company.

PL or its research analysts or its associates or his relatives do not have actual/beneficial ownership of one per cent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report.

PL or its research analysts or its associates or his relatives do not have any material conflict of interest at the time of publication of the research report.

PL or its associates might have received compensation from the subject company in the past twelve months

PL or its associates might have managed or co-managed public offering of securities for the subject company in the past twelve months or mandated by the subject company for any other assignment in the past twelve months.

PL or its associates might have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months.

PL or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months

PL or its associates might have received any compensation or other benefits from the subject company or third party in connection with the research report.

PL encourages independence in research report preparation and strives to minimize conflict in preparation of research report. PL or its analysts did not receive any compensation or other benefits from the subject Company or third party in connection with the preparation of the research report. PL or its Research Analysts do not have any material conflict of interest at the time of publication of this report.

It is confirmed that Mr. Swarnendu Bhushan- IIT, MBA Finance, Mr. Saurabh Ahire- MBA, Passed CFA Level II Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

The Research analysts for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

The research analysts for this report has not served as an officer, director or employee of the subject company PL or its research analysts have not engaged in market making activity for the subject company.

Our sales people, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

PL and its associates, their directors and employees may (a) from time to time, have a long or short position in, and buy or sell the securities of the subject company or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company or act as an advisor or lender/borrower to the subject company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

## **US Clients**

This research report is a product of Prabhudas Lilladher Pvt. Ltd., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Prabhudas Lilladher Pvt. Ltd. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Prabhudas Lilladher Pvt. Ltd. has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo").

Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

### Prabhudas Lilladher Pvt. Ltd.

3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai-400 018, India | Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209 www.plindia.com